Ravi A. Madan, MD, Discusses the Significance of the PEACE-1 Trial With Docetaxel, Abiraterone, ADT, and Radiotherapy in mCSPC
Ravi A. Madan, MD, discusses the potential impact of docetaxel, abiraterone acetate, androgen deprivation therapy, and radiotherapy on patients with metastatic castration-sensitive prostate cancer.
Ravi Madan, MD, Discusses Key Findings Utilizing PET Imaging and Tc99 Scans in Conjunction With Enzalutamide in mCRPC
Ravi Madan, MD, discusses clinical findings utilizing PET imaging and Tc99 scans in patients with metastatic castration-resistant prostate cancer who are being treated with enzalutamide
2 Commerce Drive Cranbury, NJ 08512